Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
1,857
Views
2
CrossRef citations to date
0
Altmetric
Cardiovascular

Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States

Srihari S. Naidua Westchester Medical Center, Westchester Medical Center Health Network, Valhalla, NY, USA;b New York Medical College, Valhalla, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4073-5143
ORCID Icon,
Megan B. Suttonc MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA
,
Wei Gaod Analysis Group, Inc., Boston, MA, USAORCID Iconhttps://orcid.org/0000-0002-4088-3210
ORCID Icon,
Jennifer T. Finec MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA
,
Jipan Xiee Analysis Group, Inc., Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0001-5937-0936
ORCID Icon,
Nihar R. Desaif Yale University School of Medicine, New Haven, CT, USAORCID Iconhttps://orcid.org/0000-0003-2384-2545
ORCID Icon &
Anjali T. Owensg Center for Inherited Cardiovascular Disease, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0002-9669-8495
ORCID Icon show all
Pages 682-690 | Received 13 Feb 2023, Accepted 27 Apr 2023, Published online: 11 May 2023

References

  • Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–2779.
  • Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159–e240.
  • Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–770.
  • Jain SS, Li SS, Xie J, et al. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2021;24(1):1115–1123.
  • Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106–1118.
  • Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6(12):e007161.
  • Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465–472.
  • Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387–1398.
  • Adabag AS, Kuskowski MA, Maron BJ. Determinants for clinical diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006;98(11):1507–1511.
  • Magnusson P, Palm A, Branden E, et al. Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes. Clin Epidemiol. 2017;9:403–410.
  • Maron MS, Hellawell JL, Lucove JC, et al. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117(10):1651–1654.
  • Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation. 1995;92(4):785–789.
  • Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–1254.
  • IBM Watson Health. IBM MarketScan Research Databases for Health Services Researchers [White Paper]. 2019 [cited 2021 April 20]. Available from: https://www.ibm.com/products/marketscan-research-databases/databases
  • Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
  • Lakdawala NK, Olivotto I, Day SM, et al. Associations between female sex, sarcomere variants, and clinical outcomes in hypertrophic cardiomyopathy. Circ Genom Precis Med. 2021;14(1):e003062.
  • Lemasters CS, Grosel JM. Hypertrophic cardiomyopathy: an often missed diagnosis in athletes. JAAPA. 2010;23(6):42–46.
  • Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–2239.
  • Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–228.
  • Zhao Z, Zhu Y, Fang Y, et al. Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database. J Med Econ. 2015;18(9):655–665.
  • Williams BR, Salberg L. Building a hypertrophic cardiomyopathy center of excellence. In: SS Naidu, editor. Hypertrophic cardiomyopathy. Switzerland: Springer Cham; 2019. p. 419–427.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.